IND Queens Boulevard Line

Bristol Myers Squibb Highlights Advancing Pipeline and Differentiated Research Platforms to Support Long-Term Sustainable Growth at R&D Day

Retrieved on: 
Thursday, September 14, 2023
Health, Clinical Trials, Research, Pharmaceutical, Science, Biotechnology, Bristol Myers Squibb, Janssen Pharmaceuticals, Lupus, Ruxolitinib, Probability, Eosinophilic esophagitis, Drug development, LPA1, Doctor of Philosophy, CD3, Target protein, Atrial fibrillation, GPRC5D, Cell therapy, Acute coronary syndrome, Medicine, BMY, Pulmonary fibrosis, BET, CAR, Neuroscience, NEX, Patient, Hematology, ROS1, IND Queens Boulevard Line, Biology, Canadian Aviation Regulations, Growth, Johnson & Johnson, Research and development, RRMM, BMS, R, FDA, NYSE, Idiopathic pulmonary fibrosis, BCMA, Disease, Fine chemical, Pharmaceutical industry, Vaccine

Bristol Myers Squibb (NYSE: BMY) is today holding a Research and Development (R&D) Day in New York to discuss the company’s R&D strategy and capabilities and to provide insight into its robust pipeline supporting long-term sustainable growth.

Key Points: 
  • Bristol Myers Squibb (NYSE: BMY) is today holding a Research and Development (R&D) Day in New York to discuss the company’s R&D strategy and capabilities and to provide insight into its robust pipeline supporting long-term sustainable growth.
  • “We are further enhancing our R&D engine to strengthen scientific leadership, accelerate our promising pipeline and drive increased productivity.
  • Key pipeline updates for the newly anticipated registrational assets include:
    CD19-directed NEX T cell therapy BMS-986353, expanding into clinical trials for immunologic diseases, including severe, refractory systemic lupus erythematosus.
  • “Our research strategy will enable us to increase the number and quality of potentially transformational early-stage candidates, leveraging our differentiated research platforms, and accelerate the path from proof-of-concept to regulatory approval.”
    R&D Day takes place at 9 a.m.

TScan Therapeutics Reports First Quarter 2023 Financial Results and Provides Corporate Update

Retrieved on: 
Wednesday, May 10, 2023
Amgen, GSK plc, Antigen, Partnership, Novartis Institute for Tropical Diseases, Therapy, Gene, Chief medical informatics officer, HLA, HPV16, Cancer, HCT, Toxicity, Biomedical Research, Nikos Mihas, PRAME, Trial of the century, TCR, Patient, Annual general meeting, Cell, IND Queens Boulevard Line, American Society of Gene and Cell Therapy, Bone marrow, Research, Society, Haematopoietic system, Vaccine, Pharmaceutical industry, Jet fuel, Inc.

As of March 31, 2023, TScan Therapeutics had cash and cash equivalents of $95.6 million, excluding $5.0 million of restricted cash.

Key Points: 
  • As of March 31, 2023, TScan Therapeutics had cash and cash equivalents of $95.6 million, excluding $5.0 million of restricted cash.
  • Revenue for the first quarter ended March 31, 2023, was $6.8 million, compared to $3.0 million for the first quarter ended March 31, 2022 (2022 Quarter).
  • General and administrative expenses for the first quarter ended March 31, 2023, were $7.8 million, compared to $4.5 million for the 2022 Quarter.
  • For the first quarter ended March 31, 2023, TScan Therapeutics reported a net loss of $22.6 million, compared to a net loss of $16.2 million for the 2022 Quarter.

Immunocore Reports First Quarter 2023 Financial Results and Provides Business Update

Retrieved on: 
Wednesday, May 10, 2023
Gastrointestinal cancer, PRAME, Patient, Ipilimumab, Commercial, IMC, Uveal melanoma, Infection, Research, MAD, Conference, Book, Safety, Abstract, DNA, AACR, HLA, Cancer, Record, BRAF, Medicine, Immunotherapy, TCR, CROI, James A. Schlipmann Melanoma Cancer Foundation, PIWIL1, Neoplasm, ImmTAC, Arm, HIV, OS, CTA, Fungal infection, Mum, Sale, ASCO, CTAS, American Society of Clinical Oncology, Melanoma, Annual general meeting, IND Queens Boulevard Line, Viral load, Society, Pharmaceutical industry, Cryptocurrency, Communications satellite, Immunocore, IL6

During the first quarter of 2023, KIMMTRAK became the most prescribed medicine for HLA*02:01 positive patients with mUM with over half of patients in first line (1L) receiving KIMMTRAK.

Key Points: 
  • During the first quarter of 2023, KIMMTRAK became the most prescribed medicine for HLA*02:01 positive patients with mUM with over half of patients in first line (1L) receiving KIMMTRAK.
  • In France and Germany, an estimated 80% and 70%, respectively, of first line HLA-A*02:01 positive patients with mUM treated in the first quarter received KIMMTRAK.
  • The Company launched KIMMTRAK in Austria and Israel in the first quarter and expects the commercial transition in Italy in the second quarter of this year.
  • The Company believes IMC-R117C is the first PIWIL1 targeted immunotherapy and plans to submit an IND / CTA in the fourth quarter of 2023.

CytomX Therapeutics Reports Full Year 2022 Financial Results and Provides Business Update

Retrieved on: 
Monday, March 27, 2023
Amgen, Neoplasm, Lead, Head, Science, Patient, Investment, EGFR, HNSCC, Research, PST, ADC, Safety, Bristol Myers Squibb, AE, CD3, Therapeutic index, Immunotherapy, Messenger, AbbVie, Annual report, SAN, Anemia, CD71, Webcast, Therapy, ORR, Epithelial cell adhesion molecule, Regeneron Pharmaceuticals, Bank statement, Clinical trial, EST, Trial of the century, IND Queens Boulevard Line, Interferon, BMS, Tumor microenvironment, TCB, Pharmaceutical industry, Cryptocurrency, Moderna, IND, Astellas Pharma

“2022 was an important year of transition for CytomX as we proactively restructured our organization to maximize long-term success and value creation.

Key Points: 
  • “2022 was an important year of transition for CytomX as we proactively restructured our organization to maximize long-term success and value creation.
  • CX-904 is being evaluated by CytomX in an ongoing Phase 1 study in patients with advanced solid tumors.
  • The financial results contained in this press release reflect the restated financial statements in CytomX’s most recent SEC filings.
  • ET (2 p.m. PT) to discuss the financial results and provide a business update.

Marker Therapeutics Reports Q1 2022 Operating and Financial Results

Retrieved on: 
Friday, May 13, 2022
Lymphoma, ISCT, MRD, International Society, Population, Private Securities Litigation Reform Act, Food, Research, Toxic epidermal necrolysis, EDGAR, Nasdaq, IND Queens Boulevard Line, AML, Patient, News, Marker, Form 10-K, Therapy, D, COVID-19, Orphan drug, IND, TCR, Week, Antigen, Forward-looking statement, Program, Safety, Technology, Neoplasm, Group 2, Pancreatic cancer, Lymphatic system, Cell, SEC, Investigational New Drug, GLOBE, Pharmaceutical industry, Online gambling, Company

HOUSTON, May 13, 2022 (GLOBE NEWSWIRE) -- Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications, today provided a corporate update and reported financial results for the first quarter ended March 31, 2022.

Key Points: 
  • InFebruary 2022, Marker announced the initial results of the safety lead-in stage of its Company-sponsored Phase 2 AML trial evaluating MT-401, Markers lead MultiTAA-specific T cell product candidate.
  • Topline readout of Group 2 active disease is anticipated in Q2 2022.
  • Marker announced in February 2022 that the Company intends to file INDs for MT-601, Markers second MultiTAA-specific T cell product candidate, in lymphoma and pancreatic cancer in 2022.
  • Cash Position and Guidance: At March 31, 2022, Marker had cash, cash equivalents and restricted cash of $28.8 million.

Lyell Immunopharma Reports First Quarter Financial Results and Business Highlights

Retrieved on: 
Tuesday, May 10, 2022
CAR, COVID-19, Forward-looking statement, Private Securities Litigation Reform Act, GAAP, IND, GLOBE, Company, Cell, Research, IND Queens Boulevard Line, Patient, Gene, Association, FDA, Annual report, ROR1, American Association for Cancer Research, R, TCR, Society, TIL, Lyell, SEC, GSK, AACR, G&A, Goal, Toxic shock syndrome, CEO, Annual general meeting, Large-cell lung carcinoma, Mobile phone, Pharmaceutical industry, Vaccine

We continue to progress our mission to develop T-cell therapies that can outlast and eradicate solid tumors, said LizHomans, CEO of Lyell Immunopharma.

Key Points: 
  • We continue to progress our mission to develop T-cell therapies that can outlast and eradicate solid tumors, said LizHomans, CEO of Lyell Immunopharma.
  • Lyell reported a net loss of $68.1 million for the first quarter ended March31, 2022, compared to a net loss of $55.0million for the same period in 2021.
  • A discussion of these non-GAAP financial measures, including reconciliations of the most comparable GAAP measures to non-GAAP financial measures, is presented below under Non-GAAP Financial Measures.
  • Lyell is a T-cell reprogramming company dedicated to the mastery of T cells to cure patients with solid tumors.

Recbio Announces Proposed Listing on the Main Board of the Hong Kong Stock Exchange

Retrieved on: 
Sunday, March 20, 2022
BLA, CAGR, HFMD, Adult, Vaccine, EUA, HK, NMPA, Healthcare industry, Technology, TB, Stock exchange, Pi, Solution, GMP, Science, Frost, Disease, Hong Kong Stock Exchange, Post-exposure prophylaxis, Sequoia Capital, Population, Cros, Investor, GFA, Global, Industry, Development, Shingles, WHO, III, Clinical trial, Growth, Motherboard, Core product, Board, Temasek, IPD, S. D. Warren Co. v. Maine Board of Environmental Protection, Data analysis, IND Queens Boulevard Line, Cervical cancer, COVID-19 vaccine, FDA, Recovered-memory therapy, Company, HPV, Compliance, AS04, Research, Antigen, General manager, Frost & Sullivan, Safety, Disability-adjusted life year, COVID-19, CLSA, R, Tuberculosis, Property management, Pharmaceutical industry

Recbio will open for Hong Kong Public Offering in Hong Kong at 9:00 a.m., 21 March 2022 (Monday), and close at 12:00 noon, 24 March 2022 (Thursday).

Key Points: 
  • Recbio will open for Hong Kong Public Offering in Hong Kong at 9:00 a.m., 21 March 2022 (Monday), and close at 12:00 noon, 24 March 2022 (Thursday).
  • Dealings in H Shares of Recbio on the Main Board of the Hong Kong Stock Exchange is expected to commence on 31 March 2022 (Thursday).
  • -- China Industrial Securities International Capital Limited, Haitong International Securities Company Limited, GF Securities (Hong Kong) Brokerage Limited, Essence International Securities (Hong Kong) Limited and Valuable Capital Limited (in relation to the Hong Kong Public Offering only) are the Joint Bookrunners and Joint Lead Managers.
  • Recbio is the vaccine company with a high-value vaccine portfolio driven by in-house developed technologies.

Marker Therapeutics Reports Fiscal Year 2021 Operating and Financial Results

Retrieved on: 
Thursday, March 17, 2022
Private Securities Litigation Reform Act, Therapy, Genta (company), Population, Form 10-K, MRD, Group 2, D, AML, Investigational New Drug, Forward-looking statement, Board, Lymphoma, IND, Marker, Research, SEC, Program, Antigen, Neoplasm, TCR, Food, Lymphatic system, Board of directors, Safety, Technology, IND Queens Boulevard Line, Orphan drug, Nasdaq, COVID-19, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, GLOBE, Toxic shock syndrome, News, FDA, Pancreatic cancer, EDGAR, Patient, Pharmaceutical industry, Vaccine, Airline, Company

HOUSTON, March 17, 2022 (GLOBE NEWSWIRE) -- Marker Therapeutics, Inc. (Nasdaq:MRKR), a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications, today provided a corporate update and reported financial results for the fiscal year ended December 31, 2021.

Key Points: 
  • In February 2022, Marker announced the initial results of the safety lead-in stage of its Company-sponsored Phase 2 AML trial evaluating MT-401, Markers lead MultiTAA-specific T cell product candidate.
  • On December 9, 2021, Marker announced the appointment of Katharine Knobil, M.D., to the Company's Board of Directors.
  • Marker began manufacturing MT-401 for its Phase 2 AML trial at the Companys cGMP manufacturing facility in the fourth quarter of 2021.
  • Cash Position and Guidance: At December 31, 2021, Marker had cash, cash equivalents and restricted cash of $43.5 million.

Mitsubishi Electric Wins First Contract to Supply NYCT With CBTC Wayside Equipment

Retrieved on: 
Monday, February 21, 2022
Other Manufacturing, Public Transport, Mobile, Wireless, Technology, Rail, Transport, Telecommunications, Manufacturing, Networks, Hardware, New York City Transit Authority, Union Turnpike, Westinghouse Electric Corporation, MTA Capital Construction and Development Company, Telecommunication, Metropolitan Transportation Authority, Safety, Mitsubishi Electric, QBL, MTA, CBTC, IND Queens Boulevard Line, Technology, NYCT, Jamaica–179th Street station, Rail transport

Mitsubishi Electric Corporation (TOKYO: 6503) announced today that it has been awarded a contract to supply a communications-based train control (CBTC) wayside equipment to manage train traffic on the east end of the Queens Boulevard Line (QBL) operated by New York City Transit (NYCT), which is part of the Metropolitan Transportation Authority (MTA).

Key Points: 
  • Mitsubishi Electric Corporation (TOKYO: 6503) announced today that it has been awarded a contract to supply a communications-based train control (CBTC) wayside equipment to manage train traffic on the east end of the Queens Boulevard Line (QBL) operated by New York City Transit (NYCT), which is part of the Metropolitan Transportation Authority (MTA).
  • Mitsubishi Electric will supply its first CBTC equipment outside of Japan and will become the MTAs first non-European CBTC supplier.
  • The value of the contract between MTA and Mitsubishi Electric associated with the Queens Boulevard Line East Project (QBL-E) is $62.65 million and the system is expected to enter commercial operation in 2026.
  • Mitsubishi Electrics CBTC wayside equipment will be installed on the QBL between Union Turnpike and Jamaica-179th Street stations.